MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from maturities
of investments
$43,378K
Proceeds from
convertible debt
$15,000K
Proceeds from senior
secured term loan
$12,250K
Proceeds from issuance of
common stock and...
$8,750K
Proceeds from the
exercise of stock options...
$761K
Net cash provided by
investing activities
$43,378K
Net cash provided by
financing activities
$30,048K
Effect of exchange
rates on cash, cash...
$20K
Canceled cashflow
$6,713K
Net (decrease)
increase in cash, cash...
-$1,923K
Canceled cashflow
$73,446K
Loss (gain) on
extinguishment of debt
-$62,365K
Accrued expenses and
other liabilities
$19,063K
Stock-based compensation
expense
$14,050K
Amortization of debt issuance
costs and discounts
$10,546K
Interest expense added to
debt principal
$6,258K
Accounts receivable, net
-$4,588K
Prepaid expenses and
other assets
-$4,126K
Operating lease
right-of-use assets
-$1,336K
Inventory
-$701K
Depreciation and
amortization
$296K
Payment of debt and
equity issuance costs
$6,463K
Payment of convertible
debt
$250K
Net cash used in
operating activities
-$75,369K
Canceled cashflow
$123,329K
Net loss
-$196,039K
Accounts payable
-$1,104K
Change in fair value of
embedded derivatives and...
$707K
Operating lease
liabilities
-$438K
Net amortization of
premiums and discounts on...
$410K
Back
Back
Cash Flow
source: myfinsight.com
Karyopharm Therapeutics Inc. (KPTI)
Karyopharm Therapeutics Inc. (KPTI)